259 related articles for article (PubMed ID: 29464574)
1. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.
Vollesen ALH; Amin FM; Ashina M
Neurotherapeutics; 2018 Apr; 15(2):371-376. PubMed ID: 29464574
[TBL] [Abstract][Full Text] [Related]
2. PACAP38 in human models of primary headaches.
Ashina H; Guo S; Vollesen ALH; Ashina M
J Headache Pain; 2017 Nov; 18(1):110. PubMed ID: 29453754
[TBL] [Abstract][Full Text] [Related]
3. PACAP38: Emerging Drug Target in Migraine and Cluster Headache.
Vollesen ALH; Ashina M
Headache; 2017 May; 57 Suppl 2():56-63. PubMed ID: 28485845
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.
Amin FM; Hougaard A; Schytz HW; Asghar MS; Lundholm E; Parvaiz AI; de Koning PJ; Andersen MR; Larsson HB; Fahrenkrug J; Olesen J; Ashina M
Brain; 2014 Mar; 137(Pt 3):779-94. PubMed ID: 24501094
[TBL] [Abstract][Full Text] [Related]
5. PACAP38 and PAC
Rubio-Beltrán E; Correnti E; Deen M; Kamm K; Kelderman T; Papetti L; Vigneri S; MaassenVanDenBrink A; Edvinsson L;
J Headache Pain; 2018 Aug; 19(1):64. PubMed ID: 30088106
[TBL] [Abstract][Full Text] [Related]
6. PACAP and its receptors in cranial arteries and mast cells.
Jansen-Olesen I; Hougaard Pedersen S
J Headache Pain; 2018 Feb; 19(1):16. PubMed ID: 29460121
[TBL] [Abstract][Full Text] [Related]
7. Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats.
Han X; Ran Y; Su M; Liu Y; Tang W; Dong Z; Yu S
Mol Pain; 2017; 13():1744806917720361. PubMed ID: 28776455
[TBL] [Abstract][Full Text] [Related]
8. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review.
Rustichelli C; Lo Castro F; Baraldi C; Ferrari A
Expert Opin Investig Drugs; 2020 Nov; 29(11):1269-1275. PubMed ID: 32877252
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine.
Syed AU; Koide M; Braas KM; May V; Wellman GC
J Mol Neurosci; 2012 Nov; 48(3):574-83. PubMed ID: 22766684
[TBL] [Abstract][Full Text] [Related]
10. Investigation of carbachol and PACAP38 in a human model of migraine.
Schytz HW
Dan Med Bull; 2010 Dec; 57(12):B4223. PubMed ID: 21122466
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of PACAP in ischemia.
Reglodi D; Vaczy A; Rubio-Beltran E; MaassenVanDenBrink A
J Headache Pain; 2018 Mar; 19(1):19. PubMed ID: 29500688
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery.
Tasma Z; Siow A; Harris PWR; Brimble MA; Hay DL; Walker CS
Br J Pharmacol; 2022 Feb; 179(3):435-453. PubMed ID: 34612509
[TBL] [Abstract][Full Text] [Related]
13. Temporal alterations of pituitary adenylate cyclase activating polypeptide and its receptors in a rat model induced by recurrent chemical stimulations: Relevant to chronic migraine.
Wu H; Dong Z; Liu Y; Zhang Q; Zhang M; Hu G; Yu S; Han X
Mol Pain; 2023; 19():17448069231152129. PubMed ID: 36604785
[No Abstract] [Full Text] [Related]
14. Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients.
Guo S; Vollesen AL; Hansen YB; Frandsen E; Andersen MR; Amin FM; Fahrenkrug J; Olesen J; Ashina M
Cephalalgia; 2017 Feb; 37(2):136-147. PubMed ID: 26994298
[TBL] [Abstract][Full Text] [Related]
15. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin/PAC
Rees TA; Labastida-Ramírez A; Rubio-Beltrán E
Trends Pharmacol Sci; 2023 Oct; 44(10):651-663. PubMed ID: 37543479
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
18. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
19. The PACAP receptor: a novel target for migraine treatment.
Schytz HW; Olesen J; Ashina M
Neurotherapeutics; 2010 Apr; 7(2):191-6. PubMed ID: 20430318
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention.
Pellesi L; Ashina M; Martelletti P
Expert Opin Emerg Drugs; 2024 Mar; 29(1):57-64. PubMed ID: 38337150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
